Lung Cancer

Immunotherapy Confers Survival Benefit in NSCLC Patients With Brain Metastasis

By

Sucharita Mistry, PhD

Publish Date May 18, 2022

Immunotherapy prolonged survival compared with platinum chemotherapy.

Novel Immunotherapy Combos Show Promise in Stage III Non-Small Cell Lung Cancer

By

Sucharita Mistry, PhD

Publish Date May 17, 2022

Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.

Effectiveness, Early Treatment Discontinuation Predictors of Nivolumab in Treatment of Non-Small Cell Lung Cancer

By

Jennifer Larson

Publish Date May 16, 2022

Researchers sought to determine the effectiveness of nivolumab, identify predictors of early discontinuation of treatment among patients with NSCLC, and determine median OS of nivolumab and docetaxel.

Emphysema on CT Linked to Increased Risk for Lung Cancer

Publish Date May 16, 2022

Pooled odds ratios for lung cancer increased with emphysema severity, and were higher for visual versus quantitative assessments on chest CT.

Segmentectomy “Should Be Standard” for Early-Stage Non-Small Cell Lung Cancer

By

Sucharita Mistry, PhD

Publish Date May 13, 2022

Segmentectomy prolonged 5-year overall survival in a phase 3 trial.

Lung Cancer Clinical Trials

Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)

Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)